Review



fda approved drug targets  (Human Protein Atlas)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Human Protein Atlas fda approved drug targets
    Predicted differential sensitivity to immunotherapy and targeted therapy in the EMT and metabolism subgroups . A Expression of drug targets. The heatmap highlights differentially expressed targets <t>of</t> <t>FDA-approved</t> drugs in the epithelial-mesenchymal transition (EMT) and metabolism subgroups of the Peking University Cancer Hospital (PUCH) cohort. Only the drug targets (proteins) with a log 2 fold change of abundance >1 and an adjusted P value < 0.05 between the kinomic subgroups are included. Heatmaps show drug targets (rows) arranged by hierarchical clustering and normalised protein abundance for each target. Yellow represents high protein abundance whereas navy blue represents low abundance. Subclassification of the PUCH cohort is shown at the top. The red arrows highlight the genes mentioned in the main text. B ERBB2 status in the kinomic subgroups of the Fudan cohort. ERBB2 status was assessed in the original study using a combination of IHC and fluorescence in situ hybridisation. C Pathway targets in the kinomic subgroups. The heatmap is colour-coded according to the number of predicted compounds that affect each listed process or pathway. D Tumour-infiltrating lymphocytes in the kinomic subgroups of the Asian Cancer Research Group (ACRG) cohort. E Predicted immune score and stromal score for the kinomic subgroups of the ACRG cohort. F Expression of immune receptor–ligand pairs and immunotherapy targets in the kinomic subgroups of the ACRG cohort. Only the immune molecules (genes) with a log2 fold change of mRNA expression >0.2 and an adjusted P < 0.05 between the kinomic subgroups are included. G Response prediction for PD-1 and CTLA-4 therapy in the kinomic subgroups of the ACRG cohort. The heatmap shows the significance of gene expression association between the kinomic subgroups of ACRG cohort and a cohort of melanoma patients with different immunotherapy outcomes.
    Fda Approved Drug Targets, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fda approved drug targets/product/Human Protein Atlas
    Average 86 stars, based on 1 article reviews
    fda approved drug targets - by Bioz Stars, 2026-06
    86/100 stars

    Images

    1) Product Images from "Identification and validation of an 11-kinase signature that predicts chemo- and radiosensitivity in gastric cancer"

    Article Title: Identification and validation of an 11-kinase signature that predicts chemo- and radiosensitivity in gastric cancer

    Journal: eBioMedicine

    doi: 10.1016/j.ebiom.2026.106154

    Predicted differential sensitivity to immunotherapy and targeted therapy in the EMT and metabolism subgroups . A Expression of drug targets. The heatmap highlights differentially expressed targets of FDA-approved drugs in the epithelial-mesenchymal transition (EMT) and metabolism subgroups of the Peking University Cancer Hospital (PUCH) cohort. Only the drug targets (proteins) with a log 2 fold change of abundance >1 and an adjusted P value < 0.05 between the kinomic subgroups are included. Heatmaps show drug targets (rows) arranged by hierarchical clustering and normalised protein abundance for each target. Yellow represents high protein abundance whereas navy blue represents low abundance. Subclassification of the PUCH cohort is shown at the top. The red arrows highlight the genes mentioned in the main text. B ERBB2 status in the kinomic subgroups of the Fudan cohort. ERBB2 status was assessed in the original study using a combination of IHC and fluorescence in situ hybridisation. C Pathway targets in the kinomic subgroups. The heatmap is colour-coded according to the number of predicted compounds that affect each listed process or pathway. D Tumour-infiltrating lymphocytes in the kinomic subgroups of the Asian Cancer Research Group (ACRG) cohort. E Predicted immune score and stromal score for the kinomic subgroups of the ACRG cohort. F Expression of immune receptor–ligand pairs and immunotherapy targets in the kinomic subgroups of the ACRG cohort. Only the immune molecules (genes) with a log2 fold change of mRNA expression >0.2 and an adjusted P < 0.05 between the kinomic subgroups are included. G Response prediction for PD-1 and CTLA-4 therapy in the kinomic subgroups of the ACRG cohort. The heatmap shows the significance of gene expression association between the kinomic subgroups of ACRG cohort and a cohort of melanoma patients with different immunotherapy outcomes.
    Figure Legend Snippet: Predicted differential sensitivity to immunotherapy and targeted therapy in the EMT and metabolism subgroups . A Expression of drug targets. The heatmap highlights differentially expressed targets of FDA-approved drugs in the epithelial-mesenchymal transition (EMT) and metabolism subgroups of the Peking University Cancer Hospital (PUCH) cohort. Only the drug targets (proteins) with a log 2 fold change of abundance >1 and an adjusted P value < 0.05 between the kinomic subgroups are included. Heatmaps show drug targets (rows) arranged by hierarchical clustering and normalised protein abundance for each target. Yellow represents high protein abundance whereas navy blue represents low abundance. Subclassification of the PUCH cohort is shown at the top. The red arrows highlight the genes mentioned in the main text. B ERBB2 status in the kinomic subgroups of the Fudan cohort. ERBB2 status was assessed in the original study using a combination of IHC and fluorescence in situ hybridisation. C Pathway targets in the kinomic subgroups. The heatmap is colour-coded according to the number of predicted compounds that affect each listed process or pathway. D Tumour-infiltrating lymphocytes in the kinomic subgroups of the Asian Cancer Research Group (ACRG) cohort. E Predicted immune score and stromal score for the kinomic subgroups of the ACRG cohort. F Expression of immune receptor–ligand pairs and immunotherapy targets in the kinomic subgroups of the ACRG cohort. Only the immune molecules (genes) with a log2 fold change of mRNA expression >0.2 and an adjusted P < 0.05 between the kinomic subgroups are included. G Response prediction for PD-1 and CTLA-4 therapy in the kinomic subgroups of the ACRG cohort. The heatmap shows the significance of gene expression association between the kinomic subgroups of ACRG cohort and a cohort of melanoma patients with different immunotherapy outcomes.

    Techniques Used: Expressing, Quantitative Proteomics, Fluorescence, In Situ, Hybridization, Gene Expression



    Similar Products

    fda approved drug targets  (Human Protein Atlas)
    86
    Human Protein Atlas fda approved drug targets
    Predicted differential sensitivity to immunotherapy and targeted therapy in the EMT and metabolism subgroups . A Expression of drug targets. The heatmap highlights differentially expressed targets <t>of</t> <t>FDA-approved</t> drugs in the epithelial-mesenchymal transition (EMT) and metabolism subgroups of the Peking University Cancer Hospital (PUCH) cohort. Only the drug targets (proteins) with a log 2 fold change of abundance >1 and an adjusted P value < 0.05 between the kinomic subgroups are included. Heatmaps show drug targets (rows) arranged by hierarchical clustering and normalised protein abundance for each target. Yellow represents high protein abundance whereas navy blue represents low abundance. Subclassification of the PUCH cohort is shown at the top. The red arrows highlight the genes mentioned in the main text. B ERBB2 status in the kinomic subgroups of the Fudan cohort. ERBB2 status was assessed in the original study using a combination of IHC and fluorescence in situ hybridisation. C Pathway targets in the kinomic subgroups. The heatmap is colour-coded according to the number of predicted compounds that affect each listed process or pathway. D Tumour-infiltrating lymphocytes in the kinomic subgroups of the Asian Cancer Research Group (ACRG) cohort. E Predicted immune score and stromal score for the kinomic subgroups of the ACRG cohort. F Expression of immune receptor–ligand pairs and immunotherapy targets in the kinomic subgroups of the ACRG cohort. Only the immune molecules (genes) with a log2 fold change of mRNA expression >0.2 and an adjusted P < 0.05 between the kinomic subgroups are included. G Response prediction for PD-1 and CTLA-4 therapy in the kinomic subgroups of the ACRG cohort. The heatmap shows the significance of gene expression association between the kinomic subgroups of ACRG cohort and a cohort of melanoma patients with different immunotherapy outcomes.
    Fda Approved Drug Targets, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fda approved drug targets/product/Human Protein Atlas
    Average 86 stars, based on 1 article reviews
    fda approved drug targets - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    trade name drug target s molecule type developer s owner fda approval  (Novartis)
    86
    Novartis trade name drug target s molecule type developer s owner fda approval
    Predicted differential sensitivity to immunotherapy and targeted therapy in the EMT and metabolism subgroups . A Expression of drug targets. The heatmap highlights differentially expressed targets <t>of</t> <t>FDA-approved</t> drugs in the epithelial-mesenchymal transition (EMT) and metabolism subgroups of the Peking University Cancer Hospital (PUCH) cohort. Only the drug targets (proteins) with a log 2 fold change of abundance >1 and an adjusted P value < 0.05 between the kinomic subgroups are included. Heatmaps show drug targets (rows) arranged by hierarchical clustering and normalised protein abundance for each target. Yellow represents high protein abundance whereas navy blue represents low abundance. Subclassification of the PUCH cohort is shown at the top. The red arrows highlight the genes mentioned in the main text. B ERBB2 status in the kinomic subgroups of the Fudan cohort. ERBB2 status was assessed in the original study using a combination of IHC and fluorescence in situ hybridisation. C Pathway targets in the kinomic subgroups. The heatmap is colour-coded according to the number of predicted compounds that affect each listed process or pathway. D Tumour-infiltrating lymphocytes in the kinomic subgroups of the Asian Cancer Research Group (ACRG) cohort. E Predicted immune score and stromal score for the kinomic subgroups of the ACRG cohort. F Expression of immune receptor–ligand pairs and immunotherapy targets in the kinomic subgroups of the ACRG cohort. Only the immune molecules (genes) with a log2 fold change of mRNA expression >0.2 and an adjusted P < 0.05 between the kinomic subgroups are included. G Response prediction for PD-1 and CTLA-4 therapy in the kinomic subgroups of the ACRG cohort. The heatmap shows the significance of gene expression association between the kinomic subgroups of ACRG cohort and a cohort of melanoma patients with different immunotherapy outcomes.
    Trade Name Drug Target S Molecule Type Developer S Owner Fda Approval, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/trade name drug target s molecule type developer s owner fda approval/product/Novartis
    Average 86 stars, based on 1 article reviews
    trade name drug target s molecule type developer s owner fda approval - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    fda approved drug target genes  (Human Protein Atlas)
    86
    Human Protein Atlas fda approved drug target genes
    Predicted differential sensitivity to immunotherapy and targeted therapy in the EMT and metabolism subgroups . A Expression of drug targets. The heatmap highlights differentially expressed targets <t>of</t> <t>FDA-approved</t> drugs in the epithelial-mesenchymal transition (EMT) and metabolism subgroups of the Peking University Cancer Hospital (PUCH) cohort. Only the drug targets (proteins) with a log 2 fold change of abundance >1 and an adjusted P value < 0.05 between the kinomic subgroups are included. Heatmaps show drug targets (rows) arranged by hierarchical clustering and normalised protein abundance for each target. Yellow represents high protein abundance whereas navy blue represents low abundance. Subclassification of the PUCH cohort is shown at the top. The red arrows highlight the genes mentioned in the main text. B ERBB2 status in the kinomic subgroups of the Fudan cohort. ERBB2 status was assessed in the original study using a combination of IHC and fluorescence in situ hybridisation. C Pathway targets in the kinomic subgroups. The heatmap is colour-coded according to the number of predicted compounds that affect each listed process or pathway. D Tumour-infiltrating lymphocytes in the kinomic subgroups of the Asian Cancer Research Group (ACRG) cohort. E Predicted immune score and stromal score for the kinomic subgroups of the ACRG cohort. F Expression of immune receptor–ligand pairs and immunotherapy targets in the kinomic subgroups of the ACRG cohort. Only the immune molecules (genes) with a log2 fold change of mRNA expression >0.2 and an adjusted P < 0.05 between the kinomic subgroups are included. G Response prediction for PD-1 and CTLA-4 therapy in the kinomic subgroups of the ACRG cohort. The heatmap shows the significance of gene expression association between the kinomic subgroups of ACRG cohort and a cohort of melanoma patients with different immunotherapy outcomes.
    Fda Approved Drug Target Genes, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fda approved drug target genes/product/Human Protein Atlas
    Average 86 stars, based on 1 article reviews
    fda approved drug target genes - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    fda-approved drug targets  (Human Protein Atlas)
    90
    Human Protein Atlas fda-approved drug targets
    Predicted differential sensitivity to immunotherapy and targeted therapy in the EMT and metabolism subgroups . A Expression of drug targets. The heatmap highlights differentially expressed targets <t>of</t> <t>FDA-approved</t> drugs in the epithelial-mesenchymal transition (EMT) and metabolism subgroups of the Peking University Cancer Hospital (PUCH) cohort. Only the drug targets (proteins) with a log 2 fold change of abundance >1 and an adjusted P value < 0.05 between the kinomic subgroups are included. Heatmaps show drug targets (rows) arranged by hierarchical clustering and normalised protein abundance for each target. Yellow represents high protein abundance whereas navy blue represents low abundance. Subclassification of the PUCH cohort is shown at the top. The red arrows highlight the genes mentioned in the main text. B ERBB2 status in the kinomic subgroups of the Fudan cohort. ERBB2 status was assessed in the original study using a combination of IHC and fluorescence in situ hybridisation. C Pathway targets in the kinomic subgroups. The heatmap is colour-coded according to the number of predicted compounds that affect each listed process or pathway. D Tumour-infiltrating lymphocytes in the kinomic subgroups of the Asian Cancer Research Group (ACRG) cohort. E Predicted immune score and stromal score for the kinomic subgroups of the ACRG cohort. F Expression of immune receptor–ligand pairs and immunotherapy targets in the kinomic subgroups of the ACRG cohort. Only the immune molecules (genes) with a log2 fold change of mRNA expression >0.2 and an adjusted P < 0.05 between the kinomic subgroups are included. G Response prediction for PD-1 and CTLA-4 therapy in the kinomic subgroups of the ACRG cohort. The heatmap shows the significance of gene expression association between the kinomic subgroups of ACRG cohort and a cohort of melanoma patients with different immunotherapy outcomes.
    Fda Approved Drug Targets, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fda-approved drug targets/product/Human Protein Atlas
    Average 90 stars, based on 1 article reviews
    fda-approved drug targets - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Predicted differential sensitivity to immunotherapy and targeted therapy in the EMT and metabolism subgroups . A Expression of drug targets. The heatmap highlights differentially expressed targets of FDA-approved drugs in the epithelial-mesenchymal transition (EMT) and metabolism subgroups of the Peking University Cancer Hospital (PUCH) cohort. Only the drug targets (proteins) with a log 2 fold change of abundance >1 and an adjusted P value < 0.05 between the kinomic subgroups are included. Heatmaps show drug targets (rows) arranged by hierarchical clustering and normalised protein abundance for each target. Yellow represents high protein abundance whereas navy blue represents low abundance. Subclassification of the PUCH cohort is shown at the top. The red arrows highlight the genes mentioned in the main text. B ERBB2 status in the kinomic subgroups of the Fudan cohort. ERBB2 status was assessed in the original study using a combination of IHC and fluorescence in situ hybridisation. C Pathway targets in the kinomic subgroups. The heatmap is colour-coded according to the number of predicted compounds that affect each listed process or pathway. D Tumour-infiltrating lymphocytes in the kinomic subgroups of the Asian Cancer Research Group (ACRG) cohort. E Predicted immune score and stromal score for the kinomic subgroups of the ACRG cohort. F Expression of immune receptor–ligand pairs and immunotherapy targets in the kinomic subgroups of the ACRG cohort. Only the immune molecules (genes) with a log2 fold change of mRNA expression >0.2 and an adjusted P < 0.05 between the kinomic subgroups are included. G Response prediction for PD-1 and CTLA-4 therapy in the kinomic subgroups of the ACRG cohort. The heatmap shows the significance of gene expression association between the kinomic subgroups of ACRG cohort and a cohort of melanoma patients with different immunotherapy outcomes.

    Journal: eBioMedicine

    Article Title: Identification and validation of an 11-kinase signature that predicts chemo- and radiosensitivity in gastric cancer

    doi: 10.1016/j.ebiom.2026.106154

    Figure Lengend Snippet: Predicted differential sensitivity to immunotherapy and targeted therapy in the EMT and metabolism subgroups . A Expression of drug targets. The heatmap highlights differentially expressed targets of FDA-approved drugs in the epithelial-mesenchymal transition (EMT) and metabolism subgroups of the Peking University Cancer Hospital (PUCH) cohort. Only the drug targets (proteins) with a log 2 fold change of abundance >1 and an adjusted P value < 0.05 between the kinomic subgroups are included. Heatmaps show drug targets (rows) arranged by hierarchical clustering and normalised protein abundance for each target. Yellow represents high protein abundance whereas navy blue represents low abundance. Subclassification of the PUCH cohort is shown at the top. The red arrows highlight the genes mentioned in the main text. B ERBB2 status in the kinomic subgroups of the Fudan cohort. ERBB2 status was assessed in the original study using a combination of IHC and fluorescence in situ hybridisation. C Pathway targets in the kinomic subgroups. The heatmap is colour-coded according to the number of predicted compounds that affect each listed process or pathway. D Tumour-infiltrating lymphocytes in the kinomic subgroups of the Asian Cancer Research Group (ACRG) cohort. E Predicted immune score and stromal score for the kinomic subgroups of the ACRG cohort. F Expression of immune receptor–ligand pairs and immunotherapy targets in the kinomic subgroups of the ACRG cohort. Only the immune molecules (genes) with a log2 fold change of mRNA expression >0.2 and an adjusted P < 0.05 between the kinomic subgroups are included. G Response prediction for PD-1 and CTLA-4 therapy in the kinomic subgroups of the ACRG cohort. The heatmap shows the significance of gene expression association between the kinomic subgroups of ACRG cohort and a cohort of melanoma patients with different immunotherapy outcomes.

    Article Snippet: Given the distinct molecular features observed for the EMT and metabolism subgroups, we mined FDA-approved drug targets from the Human Protein Atlas to identify subgroup-selective therapeutic targets.

    Techniques: Expressing, Quantitative Proteomics, Fluorescence, In Situ, Hybridization, Gene Expression